Screener
Madrigal Pharmaceuticals, Inc. MDGL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Madrigal Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s EBITDA margin?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported EBITDA margin of -25% in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s EBITDA margin changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s EBITDA margin increased by 58.2% year-over-year, from -59.8% to -25%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude